1
|
Cabral S. Unlocking Transcatheter Aortic Valve Replacement Expertise in Brazil: Lessons from National Data. Arq Bras Cardiol 2024; 121:e20240302. [PMID: 39140560 PMCID: PMC11341207 DOI: 10.36660/abc.20240302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2024] [Revised: 05/22/2024] [Accepted: 05/22/2024] [Indexed: 08/15/2024] Open
Affiliation(s)
- Sofia Cabral
- Centro Hospitalar Universitário de Santo AntónioPortoPortugalCentro Hospitalar Universitário de Santo António, Porto - Portugal
| |
Collapse
|
2
|
Miyoshi H, Kamiya S, Ikeda T, Narasaki S, Kondo T, Syourin D, Sumii A, Kido K, Otsuki S, Kato T, Nakamura R, Tsutsumi YM. Impact of proficiency in the transcatheter aortic valve implantation procedure on clinical outcomes: a single center retrospective study. BMC Anesthesiol 2024; 24:209. [PMID: 38907200 PMCID: PMC11191309 DOI: 10.1186/s12871-024-02594-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2024] [Accepted: 06/10/2024] [Indexed: 06/23/2024] Open
Abstract
BACKGROUND We used transcatheter aortic valve implantation (TAVI) procedure time to investigate the association between surgical team maturity and outcome. METHODS Among patients who underwent TAVI between October 2015 and November 2019, those who had Sapien™ implanted with the transfemoral artery approach were included in the analysis. We used TAVI procedure time and surgery number to draw a learning curve. Then, we divided the patients into two groups before and after the number of cases where the sigmoid curve reaches a plateau. We compared the two groups regarding the surveyed factors and investigated the correlation between the TAVI procedure time and survey factors. RESULTS Ninety-nine of 149 patients were analysed. The sigmoid curve had an inflection point in 23.2 cases and reached a plateau in 43.0 cases. Patients in the Late group had a shorter operating time, less contrast media, less radiation exposure, and less myocardial escape enzymes than the Early group. Surgical procedure time showed the strongest correlation with the surgical case number. CONCLUSION The number of cases required for surgeon proficiency for isolated Sapien™ valve implantation was 43. This number may serve as a guideline for switching the anesthesia management of TAVI from general to local anesthesia.
Collapse
Affiliation(s)
- Hirotsugu Miyoshi
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
| | - Satoshi Kamiya
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Tsuyoshi Ikeda
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Soshi Narasaki
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Takashi Kondo
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Daiki Syourin
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Ayako Sumii
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Kenshiro Kido
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Sachiko Otsuki
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Takahiro Kato
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Ryuji Nakamura
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| | - Yasuo M Tsutsumi
- Department of Anesthesiology and Critical Care, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan
| |
Collapse
|
3
|
Basman C, Landers D, Kliger C, Rodriguez-Barragan K, Yoon SH, Faraz H, Patel A, Dudiy Y, Anderson M, Kaple R. Balloon rupture during transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2024; 103:1035-1041. [PMID: 38545668 DOI: 10.1002/ccd.31029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2024] [Accepted: 03/16/2024] [Indexed: 05/01/2024]
Abstract
A distinctive complication with balloon-expandable (BE) THV platforms such as the Edwards Sapien (Edwards Lifescience) is the possibility of balloon rupture during THV deployment. Balloon rupture is a rare occurrence that can result in stroke due to fragment embolism, incomplete THV expansion, and/or vascular injury upon retrieval of the balloon. Careful evaluation of preoperative computed tomography is essential to identify high-risk cases. While annular and left ventricular outflow tract (LVOT) calcification are widely acknowledged as common risks for balloon injury, it's essential to note that balloon injury can manifest at various anatomical sites. In this review, we discuss the mechanism behind balloon rupture, methods to identify cases at a heightened risk of balloon injury, approaches to mitigate the risk of rupture, and percutaneous retrieval strategies.
Collapse
Affiliation(s)
- Craig Basman
- Department of Cardiology and Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - David Landers
- Department of Cardiology and Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Chad Kliger
- Department of Cardiothoracic Surgery, Lenox Hill Hospital, New York, New York, USA
| | - Karla Rodriguez-Barragan
- Department of Cardiology and Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Sung-Han Yoon
- Department of Cardiology and Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Haroon Faraz
- Department of Cardiology and Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Ankitkumar Patel
- Department of Cardiology and Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Yuriy Dudiy
- Department of Cardiology and Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Mark Anderson
- Department of Cardiology and Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA
| | - Ryan Kaple
- Department of Cardiology and Cardiothoracic Surgery, Hackensack University Medical Center, Hackensack, New Jersey, USA
| |
Collapse
|
4
|
Jneid H, Chikwe J, Arnold SV, Bonow RO, Bradley SM, Chen EP, Diekemper RL, Fugar S, Johnston DR, Kumbhani DJ, Mehran R, Misra A, Patel MR, Sweis RN, Szerlip M. 2024 ACC/AHA Clinical Performance and Quality Measures for Adults With Valvular and Structural Heart Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures. J Am Coll Cardiol 2024; 83:1579-1613. [PMID: 38493389 DOI: 10.1016/j.jacc.2023.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/18/2024]
|
5
|
Jneid H, Chikwe J, Arnold SV, Bonow RO, Bradley SM, Chen EP, Diekemper RL, Fugar S, Johnston DR, Kumbhani DJ, Mehran R, Misra A, Patel MR, Sweis RN, Szerlip M. 2024 ACC/AHA Clinical Performance and Quality Measures for Adults With Valvular and Structural Heart Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures. Circ Cardiovasc Qual Outcomes 2024; 17:e000129. [PMID: 38484039 DOI: 10.1161/hcq.0000000000000129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/18/2024]
Affiliation(s)
- Hani Jneid
- ACC/AHA Joint Committee on Clinical Data Standards liaison
- Society for Cardiovascular Angiography and Interventions representative
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Kumbhani DJ, Manandhar P, Bavry AA, Chhatriwalla AK, Giri J, Mack M, Carroll J, Pandey A, Kosinski A, Peterson ED, Kaneko T, de Lemos JA, Vemulapalli S. National Variation in Hospital MTEER Outcomes and Correlation With TAVR Outcomes: STS/ACC TVT Registry Analysis. JACC Cardiovasc Interv 2024; 17:505-515. [PMID: 38340102 DOI: 10.1016/j.jcin.2023.11.012] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 10/31/2023] [Accepted: 11/07/2023] [Indexed: 02/12/2024]
Abstract
BACKGROUND A single, multitiered valve center designation has been proposed to publicly identify centers with expertise for all valve therapies. The correlation between transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER) procedures is unknown. OBJECTIVES The authors sought to examine the relationship between site-level volumes and outcomes for TAVR and MTEER. We further explored variability between sites for MTEER outcomes. METHODS Using the STS/ACC TVT (Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy) national registry, TAVR and MTEER procedures at sites offering both therapies from 2013 to 2022 were examined. Sites were ranked into deciles of adjusted in-hospital and 30-day outcomes separately for TAVR and MTEER and compared. Stepwise, hierarchical multivariable models were constructed for MTEER outcomes, and the median OR was calculated. RESULTS Between 2013 and 2022, 384,394 TAVRs and 53,274 MTEERs (median annualized volumes: 93.6 and 18.8, respectively) were performed across 453 U.S. sites. Annualized TAVR and MTEER volumes were moderately correlated (r = 0.48; P < 0.001). After adjustment, 14.3% of sites had the same decile rank for TAVR and MTEER 30-day composite outcome, 50.6% were within 2 decile ranks; 35% had more discordant outcomes for the 2 procedures (P = 0.0005). For MTEER procedures, the median OR for the 30-day composite outcome was 1.57 (95% CI: 1.51-1.64), indicating a 57% variability in outcome by site. CONCLUSIONS There is modest correlation between hospital-level volumes for TAVR and MTEER but low interprocedural correlation of outcomes. For similar patients, site-level variability for mortality/morbidity following MTEER was high. Factors influencing outcomes and "centers of excellence" as a whole may differ for TAVR and MTEER.
Collapse
Affiliation(s)
- Dharam J Kumbhani
- Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
| | - Pratik Manandhar
- Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
| | - Anthony A Bavry
- Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | | | - Jay Giri
- University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Michael Mack
- Baylor Scott and White Heart Hospital, Plano, Texas, USA
| | - John Carroll
- University of Colorado School of Medicine, Aurora, Colorado, USA
| | - Ambarish Pandey
- Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Andrzej Kosinski
- Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
| | - Eric D Peterson
- Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Tsuyoshi Kaneko
- Division of Cardiothoracic Surgery, Washington University, St. Louis, Missouri, USA
| | - James A de Lemos
- Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Sreekanth Vemulapalli
- Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
| |
Collapse
|
7
|
Camporesi J, Strumia S, Di Pilla A, Paolucci M, Orsini D, Assorgi C, Cacciuttolo MG, Specchia ML. Stroke pathway performance assessment: a retrospective observational study. BMC Health Serv Res 2023; 23:1391. [PMID: 38082226 PMCID: PMC10714449 DOI: 10.1186/s12913-023-10343-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 11/17/2023] [Indexed: 12/18/2023] Open
Abstract
BACKGROUND AND AIM Performance assessment of the Stroke Pathway is a key element in healthcare quality. The aim of this study has been to carry out a retrospective assessment of the Stroke Pathway in a first level Stroke Unit in Italy, analyzing the temporal trend of the Stroke Pathway performance and the impact of the COVID-19 pandemic. METHODS A retrospective observational study was carried out analyzing data from 1/01/2010 to 31/12/2020. The following parameters were considered: volume and characteristics of patients with ischemic stroke undergoing intravenous thrombolysis, baseline modified Rankin Scale (mRS) and National Institutes of Health Stroke Scale (NIHSS) scores, Onset-to-Door (OTD), Door-To-Imaging (DTI) and Door-To-Needle (DTN) Times, mRS score 3 months after the ischemic event onset (3 m-mRS) and NIHSS score 24 h after the ischemic event onset (24 h-NIHSS). The study also compared the pre-COVID-19 pandemic period (March-December 2019) with the one immediately following it (March-December 2020). RESULTS 418 patients were included. Over time, treatment was extended to older patients (mean age from 66.3 to 75.51 years; p = 0.006) and with a higher level of baseline disability (baseline mRS score from 0.22 to 1.22; p = 0.000). A statistically significant reduction over the years was found for DTN, going from 90 min to 61 min (p = 0.000) with also an increase in the number of thrombolysis performed within the "golden hour" - more than 50% in 2019 and more of 60% in 2020. Comparing pre- and during COVID-19 pandemic periods, the number of patients remained almost unchanged, but with a significantly higher baseline disability (mRS = 1.18 vs. 0.72, p = 0.048). The pre-hospital process indicator OTD increased from 88.13 to 118.48 min, although without a statistically significant difference (p = 0.197). Despite the difficulties for hospitals due to pandemic, the hospital process indicators DTI and DTN remained substantially unchanged, as well as the clinical outcome indicators 3 m-mRS, NHISS and 24 h-NHISS. CONCLUSIONS The results of the retrospective assessment of the Stroke Pathway highlighted its positive impact both on hospital processes and patients' outcomes, even during the COVID-19 pandemic, so that the current performance is aligning itself with international goals. Moreover, the analysis showed the need of improvement actions for both hospital and pre-hospital phases. The Stroke Pathway should be improved with the thrombolysis starting in the diagnostic imaging department in order to further reduce the DTN score. Moreover, health education initiatives involving all the stakeholders should be promoted, also by using social media, to increase population awareness on timely recognition of stroke signs and symptoms and emergence medical services usage.
Collapse
Affiliation(s)
- Jacopo Camporesi
- Intensive Care Unit (ICU) Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy
| | - Silvia Strumia
- Neurology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy
| | - Andrea Di Pilla
- Direzione Sanitaria, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy.
- Alta Scuola di Economia e Management dei Sistemi Sanitari, Università Cattolica del Sacro Cuore, Roma, Italy.
| | - Matteo Paolucci
- Neurology Unit Forlì-Cesena, AUSL Romagna, Forlì, Italy
- IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
| | - Diego Orsini
- Dipartimento di Scienze della Vita e Sanità Pubblica-Sezione di Igiene, Università Cattolica del Sacro Cuore, Roma, Italy
| | - Chiara Assorgi
- Dipartimento di Scienze della Vita e Sanità Pubblica-Sezione di Igiene, Università Cattolica del Sacro Cuore, Roma, Italy
| | - Maria Gabriella Cacciuttolo
- Dipartimento di Scienze della Vita e Sanità Pubblica-Sezione di Igiene, Università Cattolica del Sacro Cuore, Roma, Italy
| | - Maria Lucia Specchia
- Dipartimento di Scienze della Vita e Sanità Pubblica-Sezione di Igiene, Università Cattolica del Sacro Cuore, Roma, Italy
- Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italy
| |
Collapse
|
8
|
Serban AM, Ionescu NS. Surgical patient registries: scoping study of challenges and solutions. J Public Health Policy 2023; 44:523-534. [PMID: 37726394 DOI: 10.1057/s41271-023-00442-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/25/2023] [Indexed: 09/21/2023]
Abstract
Patient surgical registries are essential tools for public health specialists, creating research opportunities through linkage of registry data with healthcare outcomes. However, little is known regarding data error sources in the management of surgical registries. In June 2022, we undertook a scoping study of the empirical literature including publications selected from the PUBMED and EMBASE databases. We selected 48 studies focussing on shared experiences centred around developing surgical patient registries. We identified seven types of data specific challenges, grouped in three categories- data capture, data analysis and result dissemination. Most studies underlined the risk for a high volume of missing data, non-uniform geographic representation, inclusion biases, inappropriate coding, as well as variations in analysis reporting and limitations related to the statistical analysis. Finally, to expand data usability, we discussed cost-effective ways of addressing these limitations, by citing aspects from the protocols followed by established exemplary registries.
Collapse
Affiliation(s)
- Andreea Madalina Serban
- Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd., 050474, Bucharest, Romania.
- Maria Sklodowska Curie Emergency Hospital for Children, 20 Brancoveanu Blvd., 077120, Bucharest, Romania.
| | - Nicolae Sebastian Ionescu
- Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd., 050474, Bucharest, Romania
- Maria Sklodowska Curie Emergency Hospital for Children, 20 Brancoveanu Blvd., 077120, Bucharest, Romania
| |
Collapse
|
9
|
Istrate M, Dregoesc MI, Bolboaca SD, Solomonean AG, Botis C, Stef A, Hagiu R, Moț ȘDC, Bindea DI, Oprea A, Trifan CA, Iancu AC. The Influence of the Learning Curve on Clinical Outcomes in Balloon-Expandable versus Self-Expandable Transfemoral Transcatheter Aortic Valve Implantation. Cardiology 2023; 148:335-346. [PMID: 37279710 DOI: 10.1159/000531401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 05/28/2023] [Indexed: 06/08/2023]
Abstract
INTRODUCTION Balloon-expandable (BE) and self-expandable (SE) prostheses are the main types of devices currently used in transcatheter aortic valve implantation (TAVI). Despite the different designs, clinical practice guidelines do not make any specific recommendation on the selection of one device over the other. Most operators are trained in using both BE and SE prostheses, but operator experience with each of the two designs might influence patient outcomes. The aim of this study was to compare the immediate and mid-term clinical outcomes during the learning curve in BE versus SE TAVI. METHODS The transfemoral TAVI procedures performed in a single center between July 2017 and March 2021 were grouped according to the type of implanted prosthesis. The procedures in each group were ordered according to the case sequence number. For each patient, a minimum follow-up time of 12 months was required for inclusion in the analysis. The outcomes of the BE TAVI procedures were compared with the outcomes of the SE TAVI procedures. Clinical endpoints were defined according to the Valve Academic Research Consortium 3 (VARC-3). RESULTS The median follow-up time was 28 months. Each device group included 128 patients. In the BE group, case sequence number predicted mid-term all-cause mortality at an optimal cutoff value ≤58 procedures (AUC 0.730; 95% CI: 0.644-0.805; p < 0.001), while in the SE group, the cutoff value was ≤85 procedures (AUC 0.625; 95% CI: 0.535-0.710; p = 0.04). A direct comparison of the AUC showed that case sequence number was equally adequate in predicting mid-term mortality, irrespective of prosthesis type (p = 0.11). A low case sequence number was associated with an increased rate of VARC-3 major cardiac and vascular complications (OR 0.98 95% CI: 0.96-0.99; p = 0.03) in the BE device group, and with an increased rate of post-TAVI aortic regurgitation ≥ grade II (OR 0.98; 95% CI: 0.97-0.99; p = 0.03) in the SE device group. CONCLUSIONS In transfemoral TAVI, case sequence number influenced mid-term mortality irrespective of prosthesis type, but the learning curve was longer in the case of SE devices.
Collapse
Affiliation(s)
- Mihnea Istrate
- "Iuliu Hațieganu" University of Medicine and Pharmacy, Department of Cardiology, Cluj-Napoca, Romania
| | - Mihaela Ioana Dregoesc
- "Iuliu Hațieganu" University of Medicine and Pharmacy, Department of Cardiology, Cluj-Napoca, Romania
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
| | - Sorana D Bolboaca
- Department of Medical Informatics and Biostatistics, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Aurelia G Solomonean
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
- Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Catalin Botis
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
| | - Adrian Stef
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
- Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Radu Hagiu
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
| | - Ștefan D C Moț
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
| | - Dan I Bindea
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
- Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Alexandru Oprea
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
- Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Cătălin A Trifan
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
- Department of Cardiovascular Surgery, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Adrian C Iancu
- "Iuliu Hațieganu" University of Medicine and Pharmacy, Department of Cardiology, Cluj-Napoca, Romania
- "Niculae Stăncioiu" Heart Institute, Cluj-Napoca, Romania
| |
Collapse
|
10
|
Bestehorn K, Bestehorn M, Zahn R, Perings C, Stellbrink C, Schächinger V. Transfemoral aortic valve implantation: procedural hospital volume and mortality in Germany. Eur Heart J 2023; 44:856-867. [PMID: 36459131 DOI: 10.1093/eurheartj/ehac698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 10/17/2022] [Accepted: 11/14/2022] [Indexed: 12/03/2022] Open
Abstract
AIMS Studies assessing transfemoral transcatheter aortic valve implantation (TF-TAVI) showed lower rates of in-hospital mortality at high-volume hospitals and minimum caseloads were recommended to assure quality standards. METHODS AND RESULTS All patients in the German mandatory quality assurance registry with elective or urgent TF-TAVI procedures in 2018 and 2019 at 81 and 82 hospitals, respectively, were analysed. Observed in-hospital mortality was adjusted to expected mortality by the German AKL-KATH score (O/E) as well as by the EuroScore II (O/E2). Hospital volume and O/E were correlated by regression analyses and volume quartiles. 18 763 patients (age: 81.1 ± 1.0 years, mean EuroSCORE II: 6.9 ± 1.8%) and 22 137 patients (mean age: 80.7 ± 3.5 years, mean EuroSCORE II: 6.5 ± 1.6%) were analysed in 2018 and 2019, respectively. The average observed in-hospital mortality was 2.57 ± 1.83% and 2.36 ± 1.60%, respectively. Unadjusted in-hospital mortality was significantly inversely related to hospital volume by linear regression in both years. After risk adjustment, the association between hospital volume and O/E was statistically significant in 2019 (R2 = 0.049; P = 0.046), but not in 2018 (R2 = 0.027; P = 0.14). The variance of O/E explained by the number of cases in 2019 was low (4.9%). Differences in O/E outcome between the first and the fourth quartile were not statistically significant in both years (1.10 ± 1.02 vs. 0.82 ± 0.46; P = 0.26 in 2018; 1.16 0 .97 vs. 0.74 ± 0.39; P = 0.084 in 2019). Any chosen volume cut-off could not precisely differentiate between hospitals with not acceptable quality (>95th percentile O/E of all hospitals) and those with acceptable (O/E ≤95th percentile) or above-average (O/E < 1) quality. For example, in 2019 a cut-off value of 150 would only exclude one of two hospitals with not acceptable quality, while 20 hospitals with acceptable or above-average quality (25% of all hospitals) would be excluded. CONCLUSION The association between hospital volume and in-hospital mortality in patients undergoing elective TF-TAVI in Germany in 2018 and 2019 was weak and not consistent throughout various analytical approaches, indicating no clinical relevance of hospital volume for the outcome. However, these data were derived from a healthcare system with restricted access to hospitals to perform TAVI and overall high TAVI volumes. Instead of the unprecise surrogate hospital volume, the quality of hospitals performing TF-TAVI should be directly assessed by real achieved risk-adjusted mortality.
Collapse
Affiliation(s)
- Kurt Bestehorn
- Institut für klinische Pharmakologie, Technical University Dresden, Blasewitzer Str. 86, 01307 Dresden, Germany
| | | | - Ralf Zahn
- Medizinische Klinik B, Klinikum Ludwigshafen, Bremserstr. 79, 67063 Ludwigshafen am Rhein, Germany
| | - Christian Perings
- Medizinische Klinik I, St.-Marien-Hospital, Altstadtstr. 23, 44534 Lünen, Germany
| | - Christoph Stellbrink
- Universitätsklinik für Kardiologie und Internistische Intensivmedizin, Klinikum Bielefeld, Teutoburger Str. 50, 33604 Bielefeld, Germany
| | - Volker Schächinger
- Medizinische Klinik I, Herz-Thorax Zentrum, Klinikum Fulda, Pacelliallee 4, 36043 Fulda, Germany
| |
Collapse
|
11
|
Rodés-Cabau J, Nuche J. Are contemporary TAVI results influenced by hospital volume? Eur Heart J 2023; 44:868-870. [PMID: 36527265 DOI: 10.1093/eurheartj/ehac694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Affiliation(s)
- Josep Rodés-Cabau
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.,Clínic Barcelona, Barcelona, Spain
| | - Jorge Nuche
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| |
Collapse
|
12
|
Vetrovec GW, Kaki A, Wollmuth J, Dahle TG. Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention. Heart Int 2022; 16:105-111. [PMID: 36741103 PMCID: PMC9872781 DOI: 10.17925/hi.2022.16.2.105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Accepted: 12/16/2022] [Indexed: 12/25/2022] Open
Abstract
In patients at high risk for haemodynamic instability during percutaneous coronary intervention (PCI), practitioners are increasingly opting for prophylactic mechanical circulatory support, such as the Impella® heart pump (Abiomed, Danvers, MA, USA). Though Impella-supported high-risk PCI (HRPCI) ensures haemodynamic stability during the PCI procedure, access-related complication rates have varied significantly in published studies. Reported variability in complication rates relates to many factors, including anticoagulation practices, access and closure strategy, post-procedure care and variations in event definitions. This article aims to outline optimal strategies to minimize vascular and bleeding complications during Impella-supported HRPCI based on previously identified clinical, procedural and postprocedural risk factors. Practices to reduce complications include femoral skills training, standardized protocols to optimize access, closure, anticoagulation management and post-procedural care, as well as the application of techniques and technological advances. Protocols integrating these strategies to mitigate access-related bleeding and vascular complications for Impella-supported procedures can markedly limit vascular access risk as a barrier to appropriate large-bore mechanical circulatory support use in HRPCI.
Collapse
Affiliation(s)
- George W Vetrovec
- VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA
| | - Amir Kaki
- Division of Cardiology, St. John’s Hospital, Wayne State University, Detroit, MI, USA
| | - Jason Wollmuth
- Providence Heart and Vascular Institute, Providence, OR, USA
| | - Thom G Dahle
- CentraCare Heart & Vascular Center, St. Cloud Hospital, St. Cloud, MN, USA
| | | | | | | | | |
Collapse
|
13
|
Zahid S, Din MTU, Khan MZ, Rai D, Ullah W, Sanchez-Nadales A, Elkhapery A, Khan MU, Goldsweig AM, Singla A, Fonarrow G, Balla S. Trends, Predictors, and Outcomes of 30-Day Readmission With Heart Failure After Transcatheter Aortic Valve Replacement: Insights From the US Nationwide Readmission Database. J Am Heart Assoc 2022; 11:e024890. [PMID: 35929464 PMCID: PMC9496292 DOI: 10.1161/jaha.121.024890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Data on trends, predictors, and outcomes of heart failure (HF) readmissions after transcatheter aortic valve replacement (TAVR) remain limited. Moreover, the relationship between hospital TAVR discharge volume and HF readmission outcomes has not been established. METHODS AND RESULTS The Nationwide Readmission Database was used to identify 30‐day readmissions for HF after TAVR from October 1, 2015, to November 30, 2018, using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM) codes. A total of 167 345 weighted discharges following TAVR were identified. The all‐cause readmission rate within 30 days of discharge was 11.4% (19 016). Of all the causes of 30‐day rehospitalizations, HF comprised 31.4% (5962) of all causes. The 30‐day readmission rate for HF did not show a significant decline during the study period (Ptrend=0.06); however, all‐cause readmission rates decreased significantly (Ptrend=0.03). HF readmissions were comparable between high‐ and low‐volume TAVR centers. Charlson Comorbidity Index >8, length of stay >4 days during the index hospitalization, chronic obstructive pulmonary disease, atrial fibrillation, chronic HF, preexisting pacemaker, complete heart block during index hospitalization, paravalvular regurgitation, chronic kidney disease, and end‐stage renal disease were independent predictors of 30‐day HF readmission after TAVR. HF readmissions were associated with higher mortality rates when compared with non‐HF readmissions (4.9% versus 3.3%; P<0.01). Each HF readmission within 30 days was associated with an average increased cost of $13 000 more than for each non‐HF readmission. CONCLUSIONS During the study period from 2015 to 2018, 30‐day HF readmissions after TAVR remained steady despite all‐cause readmissions decreasing significantly. All‐cause readmission mortality and HF readmission mortality also showed a nonsignificant downtrend. HF readmissions were comparable across low‐, medium‐, and high‐volume TAVR centers. HF readmission was associated with increased mortality and resource use attributed to the increased costs of care compared with non‐HF readmission. Further studies are needed to identify strategies to decrease the burden of HF readmissions and related mortality after TAVR.
Collapse
Affiliation(s)
- Salman Zahid
- Department of Medicine Rochester General Hospital Rochester NY
| | | | - Muhammad Zia Khan
- Division of Cardiology West Virginia University Heart & Vascular Institute Morgantown WV
| | - Devesh Rai
- Department of Medicine Rochester General Hospital Rochester NY
| | - Waqas Ullah
- Department of Cardiovascular Medicine Jefferson University Hospitals Philadelphia PA
| | | | - Ahmed Elkhapery
- Department of Medicine Rochester General Hospital Rochester NY
| | - Muhammad Usman Khan
- Division of Cardiology West Virginia University Heart & Vascular Institute Morgantown WV
| | - Andrew M Goldsweig
- Division of Cardiovascular Medicine University of Nebraska Medical Center Omaha NE
| | | | - Greg Fonarrow
- Division of Cardiovascular Medicine University of California Los Angeles Los Angeles CA
| | - Sudarshan Balla
- Division of Cardiology West Virginia University Heart & Vascular Institute Morgantown WV
| |
Collapse
|
14
|
Boissonnet CP, Wisner JN, Giorgi MA, Carosella L, Brescacin Castillejo C, Pissinis J, Guetta JN. Temporal Trends in Self-Expandable Transcatheter Aortic Valve Replacement in South America: A Systematic Review and Meta-Analysis. Value Health Reg Issues 2022; 30:148-160. [DOI: 10.1016/j.vhri.2022.01.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 11/24/2021] [Accepted: 01/11/2022] [Indexed: 11/29/2022]
|
15
|
Witberg G, Landes U, Talmor-Barkan Y, Richter I, Barbanti M, Valvo R, De Backer O, Ooms JF, Islas F, Marroquin L, Sedaghat A, Sugiura A, Masiero G, Armario X, Fiorina C, Arzamendi D, Santos-Martinez S, Fernández-Vázquez F, Baz JA, Steblovnik K, Mauri V, Adam M, Merdler I, Hein M, Ruile P, Codner P, Grasso C, Branca L, Estévez-Loureiro R, Benito-González T, Amat-Santos IJ, Mylotte D, Bunc M, Tarantini G, Nombela-Franco L, Søndergaard L, Van Mieghem NM, Finkelstein A, Kornowski R. Center Valve Preference and Outcomes of Transcatheter Aortic Valve Replacement: Insights From the AMTRAC Registry. JACC Cardiovasc Interv 2022; 15:1266-1274. [PMID: 35738747 DOI: 10.1016/j.jcin.2022.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Revised: 04/25/2022] [Accepted: 05/03/2022] [Indexed: 01/02/2023]
Abstract
BACKGROUND Data on outcomes of transcatheter aortic valve replacement (TAVR) using balloon-expandable valves (BEVs) or self-expandable valves (SEVs) as well as the impact of center valve preference on these outcomes are limited. OBJECTIVES The aim of this study was to compare outcomes of TAVR procedures using third-generation BEVs and SEVs stratified by center valve preference. METHODS In a multicenter registry (n = 17), 13 centers exhibited valve preference (66.6%-90% of volume) and were included. Outcomes were compared between BEVs and SEVs stratified by center valve preference. RESULTS In total, 7,528 TAVR procedures (3,854 with SEVs and 3,674 with BEVs) were included. The mean age was 81 years, and the mean Society of Thoracic Surgeons score was 5.2. Baseline characteristics were similar between BEVs and SEVs. Need for pacemaker implantation was higher with SEVs at BEV- and SEV-dominant centers (17.8% vs 9.3% [P < 0.001] and 12.7% vs 10.0% [P = 0.036], respectively; HR: 1.51; P for interaction = 0.021), risk for cerebrovascular accident was higher with SEVs at BEV-dominant but not SEV-dominant centers (3.6% vs 1.1% [P < 0.001] and 2.2% vs 1.4% [P = 0.162]; HR: 2.08; P for interaction < 0.01). Aortic regurgitation greater than mild was more frequent with SEVs at BEV-dominant centers and similar with BEVs regardless of center dominance (5.2% vs 2.8% [P < 0.001] and 3.4% vs 3.7% [P = 0.504], respectively). Two-year mortality was higher with SEVs at BEV-dominant centers but not at SEV-dominant centers (21.9% vs 16.9% [P = 0.021] and 16.8% vs 16.5% [P = 0.642], respectively; HR: 1.20; P for interaction = 0.032). CONCLUSIONS Periprocedural outcomes, aortic regurgitation greater than mild, and 2-year mortality are worse when TAVR is performed using SEVs at BEV-dominant centers. Outcomes are similar regardless of valve type at SEV-dominant centers. The present results stress the need to account for this factor when comparing BEV and SEV outcomes. (The Aortic+Mitral Transcatheter [AMTRAC] Valve Registry; NCT04031274).
Collapse
Affiliation(s)
- Guy Witberg
- Department of Cardiology, Rabin Medical Center, Petach-Tikva, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
| | - Uri Landes
- Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of Cardiology, Wolfson Medical Center, Holon, Israel
| | - Yeela Talmor-Barkan
- Department of Cardiology, Rabin Medical Center, Petach-Tikva, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Ilan Richter
- Department of Cardiology, Rabin Medical Center, Petach-Tikva, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Marco Barbanti
- Division of Cardiology, University of Catania, Catania, Italy
| | - Roberto Valvo
- Division of Cardiology, University of Catania, Catania, Italy
| | - Ole De Backer
- The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Joris F Ooms
- Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Fabian Islas
- Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain
| | - Luis Marroquin
- Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain
| | | | | | - Giulia Masiero
- Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
| | - Xavier Armario
- Department of Cardiology, Galway University Hospital, and National University of Ireland Galway, Galway, Ireland
| | | | - Dabit Arzamendi
- Hospital de Sant Creu i Sant Pau Barcelona, Barcelona, Spain
| | | | | | - Jose A Baz
- Servicio de Cardiología, Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain
| | - Klemen Steblovnik
- Department of Cardiology, University Medical Center, Ljubljana, Slovenia
| | - Victor Mauri
- Department of Cardiology, Heart Center, Faculty of Medicine, University of Cologne, Germany
| | - Matti Adam
- Department of Cardiology, Heart Center, Faculty of Medicine, University of Cologne, Germany
| | - Ilan Merdler
- Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
| | - Manuel Hein
- Department of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany
| | - Philipp Ruile
- Department of Cardiology and Angiology II, University Heart Center Freiburg-Bad Krozingen, Bad Krozingen, Germany
| | - Pablo Codner
- Department of Cardiology, Rabin Medical Center, Petach-Tikva, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Carmelo Grasso
- Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Department of Cardiology, Wolfson Medical Center, Holon, Israel
| | - Luca Branca
- Cardiovascular Department, Spedali Civili, Brescia, Italy
| | | | | | | | - Darren Mylotte
- Department of Cardiology, Galway University Hospital, and National University of Ireland Galway, Galway, Ireland
| | - Matjaz Bunc
- Department of Cardiology, University Medical Center, Ljubljana, Slovenia
| | - Giuseppe Tarantini
- Department of Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
| | - Luis Nombela-Franco
- Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain
| | - Lars Søndergaard
- The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Nicolas M Van Mieghem
- Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands
| | - Ariel Finkelstein
- Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel; Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
| | - Ran Kornowski
- Department of Cardiology, Rabin Medical Center, Petach-Tikva, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| |
Collapse
|
16
|
Bernardi FLDM, Ribeiro HB, Nombela-Franco L, Cerrato E, Maluenda G, Nazif T, Lemos PA, Sztejfman M, Lamelas P, Echeverri D, Lopes MACQ, Brito FSD, Abizaid AA, Mangione JA, Eltchaninoff H, Søndergaard L, Rodes-Cabau J. Evolução e Estado Atual das Práticas de Implante Transcateter de Válvula Aórtica na América Latina – Estudo WRITTEN LATAM. Arq Bras Cardiol 2022; 118:1085-1096. [PMID: 35703645 PMCID: PMC9345155 DOI: 10.36660/abc.20210327] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2020] [Accepted: 09/01/2021] [Indexed: 12/25/2022] Open
Abstract
Fundamento: Implante transcateter de valva aórtica (TAVI) é um procedimento adotado em todo o mundo e suas práticas evoluem rapidamente. Variações regionais e temporais são esperadas. Objetivo: Comparar a prática de TAVI na América Latina com aquela no resto do mundo e avaliar suas mudanças na América Latina de 2015 a 2020. Método: A pesquisa foi realizada em centros de TAVI em todo o mundo entre março e setembro de 2015, e novamente nos centros latino-americanos entre julho de 2019 e janeiro de 2020. As seguintes questões foram abordadas: i) informação geral sobre os centros; ii) avaliação pré-TAVI; iii) técnicas do procedimento; iv) conduta pós-TAVI; v) seguimento. As respostas da pesquisa dos centros latino-americanos em 2015 (LATAM15) foram comparadas àquelas dos centros no resto do mundo (WORLD15) e ainda àquelas da pesquisa dos centros latino-americanos de 2020 (LATAM20). Adotou-se o nível de significância de 5% na análise estatística. Resultados: 250 centros participaram da pesquisa em 2015 (LATAM15=29; WORLD15=221) e 46 na avaliação LATAM20. No total, foram 73.707 procedimentos, sendo que os centros WORLD15 realizaram, em média, 6 e 3 vezes mais procedimentos do que os centros LATAM15 e LATAM20, respectivamente. Os centros latino-americanos realizaram menor número de TAVI minimalista do que os do restante do mundo, mas aumentaram significativamente os procedimentos menos invasivos após 5 anos. Quanto à assistência pós-procedimento, observaram-se menor tempo de telemetria e de manutenção do marca-passo temporário, além de menor uso de terapia dupla antiplaquetária nos centros LATAM20. Conclusão: A despeito do volume de procedimentos ainda significativamente menor, muitos aspectos da prática de TAVI nos centros latino-americanos evoluíram recentemente, acompanhando a tendência dos centros dos países desenvolvidos.
Collapse
|
17
|
Gray R, Sarathy K. Trends in Transcatheter Aortic Valve Implantation in Australia. Interv Cardiol 2022; 17:e03. [PMID: 35401791 PMCID: PMC8977994 DOI: 10.15420/icr.2021.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Accepted: 12/05/2021] [Indexed: 11/21/2022] Open
Abstract
Aortic valve stenosis is the most common valvular lesion in Australia, with a rising prevalence in line with the ageing population. Recent trials have demonstrated the efficacy of transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement in consecutively lower surgical risk patient cohorts. Despite this, the current indication for TAVI in Australia is for the treatment of severe symptomatic aortic stenosis in patients who are of prohibitive or high surgical risk and ultimately deemed suitable by a heart team. This article summarises the trends in TAVI in Australia over the last 5 years in terms of funding, accreditation and service delivery, as well as advances in technique, technology, patient selection and local outcomes.
Collapse
Affiliation(s)
- Rhys Gray
- Department of Cardiology, Prince of Wales Hospital, Sydney, Australia; Prince of Wales Clinical School, University of New South Wales Medicine, Sydney, Australia; Eastern Heart Clinic, Sydney, Australia
| | - Kiran Sarathy
- Department of Cardiology, Prince of Wales Hospital, Sydney, Australia; Prince of Wales Clinical School, University of New South Wales Medicine, Sydney, Australia; Eastern Heart Clinic, Sydney, Australia
| |
Collapse
|
18
|
Mentias A, Keshvani N, Desai MY, Kumbhani DJ, Sarrazin MV, Gao Y, Kapadia S, Peterson ED, Mack M, Girotra S, Pandey A. Risk-Adjusted, 30-Day Home Time After Transcatheter Aortic Valve Replacement as a Hospital-Level Performance Metric. J Am Coll Cardiol 2022; 79:132-144. [PMID: 35027108 PMCID: PMC10535368 DOI: 10.1016/j.jacc.2021.10.038] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 10/14/2021] [Accepted: 10/18/2021] [Indexed: 11/21/2022]
Abstract
BACKGROUND Patient-centric measures of hospital performance for transcatheter aortic valve replacement (TAVR) are needed. OBJECTIVES This study evaluated 30-day, risk-adjusted home time as a hospital performance metric for patients who underwent TAVR. METHODS This study identified 160,792 Medicare beneficiaries who underwent elective TAVR from 2015 to 2019. Home time was calculated for each patient as the number of days alive and spent outside the hospital, skilled nursing facility (SNF), and long-term acute care facility for 30 days after the TAVR procedure date. Correlations between risk-adjusted, 30-day home time and other metrics (30-day, risk-adjusted readmission rate [RSRR], 30-day, risk-adjusted mortality rate [RSMR], and annual TAVR volume) were estimated using Pearson's correlation. Meaningful upward or downward reclassification (≥2 quartile ranks) in hospital performance based on quartiles of risk-adjusted, 30-day home time compared with quartiles of other measures were assessed. RESULTS Median risk-adjusted, 30-day home time was 27.4 days (interquartile range [IQR]: 26.3-28.5 days). The largest proportion of days lost from 30-day home time was hospital stay after TAVR and SNF stay. An inverse correlation was observed between hospital-level, risk-adjusted, 30-day home time and 30-day RSRR (r = -0.465; P < 0.001) and 30-day RSMR (r = -0.3996; P < 0.001). The use of the 30-day, risk-adjusted home time was associated with reclassification in hospital performance rank hospitals compared with other metrics (9.1% up-classified, 11.2% down-classified vs RSRR; 9.1% up-classified, 10.3% down-classified vs RSMR; and 20.1% up-classified, 19.3% down-classified vs annual TAVR volume). CONCLUSIONS Risk-adjusted, 30-day home time represents a novel patient-centered performance metric for TAVR hospitals that may provide a complimentary assessment to currently used metrics.
Collapse
Affiliation(s)
- Amgad Mentias
- Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
| | - Neil Keshvani
- Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Milind Y Desai
- Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Dharam J Kumbhani
- Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Mary Vaughan Sarrazin
- Center for Access and Delivery Research and Evaluation, Iowa City Veterans Affairs Medical Center, Iowa City, Iowa, USA; Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA
| | - Yubo Gao
- Center for Access and Delivery Research and Evaluation, Iowa City Veterans Affairs Medical Center, Iowa City, Iowa, USA; Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA
| | - Samir Kapadia
- Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
| | - Eric D Peterson
- Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
| | - Michael Mack
- Division of Cardiology, Baylor Scott and White Health, Plano, Texas, USA
| | - Saket Girotra
- Center for Access and Delivery Research and Evaluation, Iowa City Veterans Affairs Medical Center, Iowa City, Iowa, USA; Division of Cardiovascular Diseases, Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA
| | - Ambarish Pandey
- Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
| |
Collapse
|
19
|
Lauck SB, Baron SJ, Irish W, Borregaard B, Moore KA, Gunnarsson CL, Clancy S, Wood DA, Thourani VH, Webb JG, Wijeysundera HC. Temporal Changes in Mortality After Transcatheter and Surgical Aortic Valve Replacement: Retrospective Analysis of US Medicare Patients (2012-2019). J Am Heart Assoc 2021; 10:e021748. [PMID: 34581191 PMCID: PMC8751862 DOI: 10.1161/jaha.120.021748] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background The treatment of aortic stenosis is evolving rapidly. Pace of change in the care of patients undergoing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) differs. We sought to determine differences in temporal changes in 30‐day mortality, 30‐day readmission, and length of stay after TAVR and SAVR. Methods and Results We conducted a retrospective cohort study of patients treated in the United States between 2012 and 2019 using data from the Medicare Data Set Analytic File 100% Fee for Service database. We included consecutive patients enrolled in Medicare Parts A and B and aged ≥65 years who had SAVR or transfemoral TAVR. We defined 3 study cohorts, including all SAVR, isolated SAVR (without concomitant procedures), and elective isolated SAVR and TAVR. The primary end point was 30‐day mortality; secondary end points were 30‐day readmission and length of stay. Statistical models controlled for patient demographics, frailty measured by the Hospital Frailty Risk Score, and comorbidities measured by the Elixhauser Comorbidity Index (ECI). Cox proportional hazard models were developed with TAVR versus SAVR as the main covariates with a 2‐way interaction term with index year. We repeated these analyses restricted to full aortic valve replacement hospitals offering both SAVR and TAVR. The main study cohort included 245 269 patients with SAVR and 188 580 patients with TAVR, with mean±SD ages 74.3±6.0 years and 80.7±6.9 years, respectively, and 36.5% and 46.2% female patients, respectively. Patients with TAVR had higher ECI scores (6.4±3.6 versus 4.4±3) and were more frail (55.4% versus 33.5%). Total aortic valve replacement volumes increased 61% during the 7‐year span; TAVR volumes surpassed SAVR in 2017. The magnitude of mortality benefit associated with TAVR increased until 2016 in the main cohort (2012: hazard ratio [HR], 0.76 [95% CI, 0.67–0.86]; 2016: HR, 0.39 [95% CI, 0.36–0.43]); although TAVR continued to have lower mortality rates from 2017 to 2019, the magnitude of benefit over SAVR was attenuated. A similar pattern was seen with readmission, with a lower risk of readmission from 2012 to 2016 for patients with TAVR (2012: HR, 0.68 [95% CI, 0.63–0.73]; 2016: HR, 0.43 [95% CI, 0.41–0.45]) followed by a lesser difference from 2017 to 2019. Year over year, TAVR was associated with increasingly shorter lengths of stay compared with SAVR (2012: HR, 1.91 [95% CI, 1.84–1.98]; 2019: HR, 5.34 [95% CI, 5.22–5.45]). These results were consistent in full aortic valve replacement hospitals. Conclusions The rate of improvement in TAVR outpaced SAVR until 2016, with the recent presence of U‐shaped phenomena suggesting a narrowing gap between outcomes. Future longitudinal research is needed to determine the long‐term implications of lowering risk profiles across treatment options to guide case selection and clinical care.
Collapse
Affiliation(s)
- Sandra B Lauck
- Centre for Heart Valve Innovation University of British Columbia Vancouver Canada
| | - Suzanne J Baron
- Department of Cardiology Lahey Hospital & Medical Center Burlington MA
| | - William Irish
- Department of Public Health Brody School of Medicine East Carolina University Greenville NC
| | - Britt Borregaard
- Department of Cardiology Odense University Hospital Odense Denmark
| | | | | | | | - David A Wood
- Centre for Heart Valve Innovation University of British Columbia Vancouver Canada
| | | | - John G Webb
- Centre for Heart Valve Innovation University of British Columbia Vancouver Canada
| | | |
Collapse
|
20
|
Nazif TM, Cahill TJ, Daniels D, McCabe JM, Reisman M, Chakravarty T, Makkar R, Krishnaswamy A, Kapadia S, Chehab BM, Wang J, Spies C, Rodriguez E, Kaneko T, Hahn RT, Leon MB, George I. Real-World Experience With the SAPIEN 3 Ultra Transcatheter Heart Valve: A Propensity-Matched Analysis From the United States. Circ Cardiovasc Interv 2021; 14:e010543. [PMID: 34433290 DOI: 10.1161/circinterventions.121.010543] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Tamim M Nazif
- Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York City, NY (T.M.N., T.J.C., R.T.H., M.B.L., I.G.)
| | - Thomas J Cahill
- Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York City, NY (T.M.N., T.J.C., R.T.H., M.B.L., I.G.)
| | - David Daniels
- Bay Area Structural Heart (BASH) @ Sutter Health, Burlingame, CA (D.D., C.S.)
| | - James M McCabe
- University of Washington Medical Center, Seattle (J.M.M., M.R.)
| | - Mark Reisman
- University of Washington Medical Center, Seattle (J.M.M., M.R.)
| | | | - Raj Makkar
- Cedars-Sinai Medical Center, Los Angeles, CA (T.C., R.M.)
| | | | - Samir Kapadia
- Cleveland Clinic Foundation, Cleveland, OH (A.K., S.K.)
| | | | - John Wang
- MedStar Union Memorial Hospital, Baltimore, MD (J.W.)
| | - Christian Spies
- Bay Area Structural Heart (BASH) @ Sutter Health, Burlingame, CA (D.D., C.S.)
| | | | | | - Rebecca T Hahn
- Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York City, NY (T.M.N., T.J.C., R.T.H., M.B.L., I.G.)
| | - Martin B Leon
- Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York City, NY (T.M.N., T.J.C., R.T.H., M.B.L., I.G.)
| | - Isaac George
- Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York City, NY (T.M.N., T.J.C., R.T.H., M.B.L., I.G.)
| |
Collapse
|
21
|
2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg 2021; 162:e183-e353. [PMID: 33972115 DOI: 10.1016/j.jtcvs.2021.04.002] [Citation(s) in RCA: 90] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
22
|
Kolte D, Kennedy K, Wasfy JH, Jena AB, Elmariah S. Hospital Variation in 30-Day Readmissions Following Transcatheter Aortic Valve Replacement. J Am Heart Assoc 2021; 10:e021350. [PMID: 33938233 PMCID: PMC8200708 DOI: 10.1161/jaha.120.021350] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Data on hospital variation in 30-day readmission rates after transcatheter aortic valve replacement (TAVR) are limited. Further, whether such variation is explained by differences in hospital characteristics and hospital practice patterns remains unknown. Methods and Results We used the 2017 Nationwide Readmissions Database to identify hospitals that performed at least 5 TAVRs. Hierarchical logistic regression models were used to examine between-hospital variation in 30-day all-cause risk-standardized readmission rate (RSRR) after TAVR and to explore reasons underlying hospital variation in 30-day RSRR. The study included 27 091 index TAVRs performed across 325 hospitals. The median (interquartile range) hospital-level 30-day RSRR was 11.9% (11.1%-12.8%) ranging from 8.8% to 16.5%. After adjusting for differences in patient characteristics, there was significant between-hospital variation in 30-day RSRR (hospital odds ratio, 1.59; 95% CI, 1.39-1.77). Differences in length of stay and discharge disposition accounted for 15% of the between-hospital variance in RSRRs. There was no significant association between hospital characteristics and 30-day readmission rates after TAVR. There was statistically significant but weak correlation between 30-day RSRR after TAVR and that after surgical aortic valve replacement, percutaneous coronary intervention, acute myocardial infarction, heart failure, and pneumonia (r=0.132-0.298; P<0.001 for all). Causes of 30-day readmission varied across hospitals, with noncardiac readmissions being more common at the bottom 5% hospitals (ie, those with the highest RSRRs). Conclusions There is significant variation in 30-day RSRR after TAVR across hospitals that is not entirely explained by differences in patient or hospital characteristics as well as hospital-wide practice patterns. Noncardiac readmissions are more common in hospitals with the highest RSRRs.
Collapse
Affiliation(s)
- Dhaval Kolte
- Cardiology Division Department of Medicine Massachusetts General HospitalHarvard Medical School Boston MA
| | - Kevin Kennedy
- Saint Luke's Mid America Heart Institute Kansas City MO
| | - Jason H Wasfy
- Cardiology Division Department of Medicine Massachusetts General HospitalHarvard Medical School Boston MA
| | - Anupam B Jena
- Department of Health Care Policy Harvard Medical School and Department of Medicine Massachusetts General Hospital Boston MA
| | - Sammy Elmariah
- Cardiology Division Department of Medicine Massachusetts General HospitalHarvard Medical School Boston MA
| |
Collapse
|
23
|
Kapadia SR, Krishnaswamy A. Valve Choice in TAVR: A Complex Equation to Solve. J Am Coll Cardiol 2021; 77:2216-2218. [PMID: 33926658 DOI: 10.1016/j.jacc.2021.03.294] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 03/16/2021] [Indexed: 11/18/2022]
Affiliation(s)
- Samir R Kapadia
- Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA.
| | - Amar Krishnaswamy
- Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA
| |
Collapse
|
24
|
Pesarini G, Venturi G, Tavella D, Gottin L, Lunardi M, Mirandola E, Onorati F, Faggian G, Ribichini F. Real World Performance Evaluation of Transcatheter Aortic Valve Implantation. J Clin Med 2021; 10:jcm10091890. [PMID: 33925582 PMCID: PMC8123878 DOI: 10.3390/jcm10091890] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 04/14/2021] [Accepted: 04/19/2021] [Indexed: 12/20/2022] Open
Abstract
Background: The aim of this research is to describe the performance over time of transcatheter aortic valve implantations (TAVIs) in a high-volume center with a contemporary, real-world population. Methods: Patients referred for TAVIs at the University Hospital of Verona were prospectively enrolled. By cumulative sum failures analysis (CUSUM), procedural-control curves for standardized combined endpoints—as defined by the Valve Academic Research Consortium-2 (VARC-2)—were calculated and analyzed over time. Acceptable and unacceptable limits were derived from recent studies on TAVI in intermediate and low-risk patients to fit the higher required standards for current indications. Results: A total of 910 patients were included. Baseline risk scores significantly reduced over time. Complete procedural control was obtained after approximately 125 and 190 cases for device success and early safety standardized combined endpoints, respectively. High risk patients (STS ≥ 8) had poorer outcomes, especially in terms of VARC-2 clinical efficacy, and required a higher case load to maintain in-control and proficient procedures. Clinically relevant single endpoints were all influenced by operator’s experience as well. Conclusions: Quality-control analysis for contemporary TAVI interventions based on standardized endpoints suggests the need for relevant operator’s experience to achieve and maintain optimal clinical results, especially in higher-risk subjects.
Collapse
Affiliation(s)
- Gabriele Pesarini
- Division of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy; (G.V.); (D.T.); (M.L.); (E.M.); (F.R.)
- Correspondence: ; Tel.: +39-045-812-2320
| | - Gabriele Venturi
- Division of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy; (G.V.); (D.T.); (M.L.); (E.M.); (F.R.)
| | - Domenico Tavella
- Division of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy; (G.V.); (D.T.); (M.L.); (E.M.); (F.R.)
| | - Leonardo Gottin
- Division of Anaesthesiology, University of Verona, 37126 Verona, Italy;
| | - Mattia Lunardi
- Division of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy; (G.V.); (D.T.); (M.L.); (E.M.); (F.R.)
| | - Elena Mirandola
- Division of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy; (G.V.); (D.T.); (M.L.); (E.M.); (F.R.)
| | - Francesco Onorati
- Division of Cardiac Surgery, University of Verona, 37126 Verona, Italy; (F.O.); (G.F.)
| | - Giuseppe Faggian
- Division of Cardiac Surgery, University of Verona, 37126 Verona, Italy; (F.O.); (G.F.)
| | - Flavio Ribichini
- Division of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy; (G.V.); (D.T.); (M.L.); (E.M.); (F.R.)
| |
Collapse
|
25
|
Fukuda H, Kiyohara K, Sato D, Kitamura T, Kodera S. A Real-World Comparison of 1-Year Survival and Expenditures for Transcatheter Aortic Valve Replacements: SAPIEN 3 Versus CoreValve Versus Evolut R. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2021; 24:497-504. [PMID: 33840427 DOI: 10.1016/j.jval.2020.10.022] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 07/30/2020] [Accepted: 10/23/2020] [Indexed: 06/12/2023]
Abstract
OBJECTIVES New versions of balloon-expandable and self-expandable valves for transcatheter aortic valve replacement (TAVR) have been developed, but few studies have examined the outcomes associated with these devices using national-level data. This study aimed to elucidate the clinical and economic outcomes of TAVR for aortic stenosis in Japan through an analysis of real-world data. METHODS This retrospective cohort study was performed using data from patients with aortic stenosis who had undergone transfemoral TAVR with Edwards SAPIEN 3, Medtronic CoreValve, or Medtronic Evolut R valves throughout Japan from April 2016 to March 2018. Pacemaker implantation, mortality, and health expenditure were examined for each valve type during hospitalization and at 1 month, 3 months, 6 months, and 1 year. Generalized linear regression models and Cox proportional hazards models were used to examine the associations between the valve types and outcomes. RESULTS We analyzed 7244 TAVR cases (SAPIEN 3: 5276, CoreValve: 418, and Evolut R: 1550) across 145 hospitals. The adjusted 1-year expenditures for SAPIEN 3, CoreValve, and Evolut R were $79 402, $76 125, and $75 527, respectively; SAPIEN 3 was significantly more expensive than the other valves (P < .05). The pacemaker implantation hazard ratios (95% confidence intervals) for CoreValve and Evolut R were significantly higher (P < .001) than SAPIEN 3 at 2.61 (2.07-3.27) and 1.80 (1.53-2.12), respectively. The mortality hazard ratios (95% confidence intervals) for CoreValve and Evolut R were not significant at 1.11 (0.84-1.46) and 1.22 (0.97-1.54), respectively. CONCLUSIONS SAPIEN 3 users had generally lower pacemaker implantation and mortality but higher expenditures than CoreValve and Evolut R users.
Collapse
Affiliation(s)
- Haruhisa Fukuda
- Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
| | - Kosuke Kiyohara
- Department of Food Science, Otsuma Women's University, Tokyo, Japan
| | - Daisuke Sato
- Center for Next Generation of Community Health, Chiba University Hospital, Chiba, Japan
| | - Tetsuhisa Kitamura
- Division of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan
| | - Satoshi Kodera
- Department of Cardiovascular Medicine, The University of Tokyo Hospital, Tokyo, Japan
| |
Collapse
|
26
|
Russo MJ, Okoh AK, Stump K, Smith M, Erinne I, Johannesen J, Chaudhary A, Chiricolo A, Hakeem A, Lemaire A, Lee LY, Chen C. Safety and Feasibility of Same Day Discharge after Transcatheter Aortic Valve Replacement Post COVID-19. STRUCTURAL HEART : THE JOURNAL OF THE HEART TEAM 2021; 5:182-185. [PMID: 35378799 PMCID: PMC8968999 DOI: 10.1080/24748706.2020.1853861] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/08/2021] [Revised: 09/02/2021] [Accepted: 10/05/2021] [Indexed: 12/12/2022]
Affiliation(s)
- Mark J Russo
- Department of Surgery, Division of Cardiac Surgery, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.,Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
| | - Alexis K Okoh
- Department of Surgery, Division of Cardiac Surgery, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.,Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
| | - Katherine Stump
- Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
| | - Meghan Smith
- Department of Surgery, Division of Cardiac Surgery, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA
| | - Ikenna Erinne
- Department of Medicine; Division of Cardiology, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA
| | - Justin Johannesen
- Department of Medicine; Division of Cardiology, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA
| | - Ashok Chaudhary
- Department of Medicine; Division of Cardiology, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA
| | - Antonio Chiricolo
- Department of Medicine; Division of Cardiology, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA
| | - Abdul Hakeem
- Department of Medicine; Division of Cardiology, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA
| | - Anthony Lemaire
- Department of Surgery, Division of Cardiac Surgery, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.,Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
| | - Leonard Y Lee
- Department of Surgery, Division of Cardiac Surgery, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.,Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
| | - Chunguang Chen
- Department of Surgery, Division of Cardiac Surgery, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA.,Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.,Department of Medicine; Division of Cardiology, Robert Wood Johnson University Hospital, New Brunswick, New Jersey, USA
| |
Collapse
|
27
|
Ando T, Ashraf S, Kuno T, Briasoulis A, Takagi H, Grines C, Malik A. Hospital variation of 30-day readmission rate following transcatheter aortic valve implantation. Heart 2021; 108:219-224. [PMID: 33627399 DOI: 10.1136/heartjnl-2020-318583] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Revised: 02/04/2021] [Accepted: 02/08/2021] [Indexed: 11/03/2022] Open
Abstract
OBJECTIVES Thirty-day readmission rate is one of the hospital quality metrics. Outcomes of transcatheter aortic valve implantation (TAVI) have improved significantly, but it remains unclear whether hospital-level variance in 30-day readmission rate exists in the contemporary TAVI era. METHODS From the 2017 US Nationwide Readmission Database, endovascular TAVI were identified. The unadjusted 30-day readmission rate and 30-day risk-standardised readmission rate (RSRR) were calculated and we then conducted model testing to determine the relative contribution of hospital characteristics, patient-level covariates and economic status to the variation in readmission rates observed between the hospitals. RESULTS A total of 44 899 TAVI from 338 hospitals were identified. The range of unadjusted 30-day readmission rate and 30-day RSRR was 2.0%-33.3% and 9.4%-15.3%, respectively. Median 30-day RSRR was 11.8% and there was a significant hospital-level variation (median OR 1.22, 95% CI 1.16 to 1.32, p<0.01) and this was similar in both readmissions caused due to major cardiac and non-cardiac conditions. Patient, hospital and economic factors accounted for 9.6%, 1.9% and 3.8% of the variability in hospital readmission rate, respectively. CONCLUSIONS There was significant hospital-level variation in 30-day RSRR following TAVI. Further measures are required to mitigate this variance in the readmission rate.
Collapse
Affiliation(s)
- Tomo Ando
- Division of Cardiology, Kawasaki Saiwai Hospital, Kawasaki, Japan
| | - Said Ashraf
- Division of Interventional Cardiology, New York University Langone Medical Center, New York City, New York, USA
| | - Toshiki Kuno
- Department of Internal Medicine, Mount Sinai Beth Israel Hospital, New York City, New York, USA
| | | | - Hisato Takagi
- Division of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan
| | - Cindy Grines
- Division of Interventional Cardiology, Northside Hospital Cardiovascular Institute, Atlanta, Georgia, USA
| | - Aaqib Malik
- Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York, USA
| |
Collapse
|
28
|
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2021; 143:e72-e227. [PMID: 33332150 DOI: 10.1161/cir.0000000000000923] [Citation(s) in RCA: 555] [Impact Index Per Article: 185.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
29
|
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2021; 77:e25-e197. [PMID: 33342586 DOI: 10.1016/j.jacc.2020.11.018] [Citation(s) in RCA: 837] [Impact Index Per Article: 279.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
30
|
Vetrovec GW, Kaki A, Dahle TG. A Review of Bleeding Risk with Impella-supported High-risk Percutaneous Coronary Intervention. Heart Int 2020; 14:92-99. [PMID: 36276510 PMCID: PMC9524743 DOI: 10.17925/hi.2020.14.2.92] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Accepted: 12/29/2020] [Indexed: 09/09/2024] Open
Abstract
Complex, high-risk percutaneous coronary intervention (HR-PCI) is increasingly being performed, often with mechanical circulatory support (MCS), though to date, there are limited randomised data on the efficacy of MCS for HR-PCI. The majority of MCS is provided by intra-aortic balloon pumps, but increasingly Impella® (Abiomed, Danvers, MA, USA) heart pumps are being used. While the Impella pumps provide greater increases in cardiac output, these devices require large bore access, which has been associated with an increased risk of bleeding and vascular complications. Decisions regarding the use of Impella are often based on risk-benefit considerations, with Impella-related bleeding risk being a major factor that can impact decisions for planned use. While bleeding risk related to large bore access is a concern, published data on the risk have been quite variable. Thus, the goal of this article is to provide a comprehensive review of reports describing bleeding and vascular complications for Impella-supported HR-PCI.
Collapse
Affiliation(s)
- George W Vetrovec
- Pauley Heart Center, Virginia Commonwealth University (VCU) Health, VCU, Richmond, VA, USA
| | - Amir Kaki
- Division of Cardiology, St. John’s Hospital, Wayne State University, Detroit, MI, USA
| | - Thom G Dahle
- Centracare Heart & Vascular Center, St. Cloud Hospital, St. Cloud, MN, USA
| |
Collapse
|
31
|
Makkar RR, Cheng W, Waksman R, Satler LF, Chakravarty T, Groh M, Abernethy W, Russo MJ, Heimansohn D, Hermiller J, Worthley S, Chehab B, Cunningham M, Matthews R, Ramana RK, Yong G, Ruiz CE, Chen C, Asch FM, Nakamura M, Jilaihawi H, Sharma R, Yoon SH, Pichard AD, Kapadia S, Reardon MJ, Bhatt DL, Fontana GP. Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. Lancet 2020; 396:669-683. [PMID: 32593323 DOI: 10.1016/s0140-6736(20)31358-1] [Citation(s) in RCA: 78] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Revised: 06/08/2020] [Accepted: 06/09/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND Randomised trial data assessing the safety and efficacy of the self-expanding intra-annular Portico transcatheter aortic valve system (Abbott Structural Heart, St Paul, MN, USA) compared with any commercially available valves are needed to compare performance among designs. METHODS In this prospective, multicentre, non-inferiority, randomised controlled trial (the Portico Re-sheathable Transcatheter Aortic Valve System US Investigational Device Exemption trial [PORTICO IDE]), high and extreme risk patients with severe symptomatic aortic stenosis were recruited from 52 medical centres experienced in performing transcatheter aortic valve replacement in the USA and Australia. Patients were eligible if they were aged 21 years or older, in New York Heart Association functional class II or higher, and had severe native aortic stenosis. Eligible patients were randomly assigned (1:1) using permuted block randomisation (block sizes of 2 and 4) and stratified by clinical investigational site, surgical risk cohort, and vascular access method, to transcatheter aortic valve replacement with the first generation Portico valve and delivery system or a commercially available valve (either an intra-annular balloon-expandable Edwards-SAPIEN, SAPIEN XT, or SAPIEN 3 valve [Edwards LifeSciences, Irvine, CA, USA]; or a supra-annular self-expanding CoreValve, Evolut-R, or Evolut-PRO valve [Medtronic, Minneapolis, MN, USA]). Investigational site staff, implanting physician, and study participant were unmasked to treatment assignment. Core laboratories and clinical event assessors were masked to treatment allocation. The primary safety endpoint was a composite of all-cause mortality, disabling stroke, life-threatening bleeding requiring transfusion, acute kidney injury requiring dialysis, or major vascular complication at 30 days. The primary efficacy endpoint was all-cause mortality or disabling stroke at 1 year. Clinical outcomes and valve performance were assessed up to 2 years after the procedure. Primary analyses were by intention to treat and the Kaplan-Meier method to estimate event rates. The non-inferiority margin was 8·5% for primary safety and 8·0% for primary efficacy endpoints. This study is registered with ClinicalTrials.gov, NCT02000115, and is ongoing. FINDINGS Between May 30 and Sept 12, 2014, and between Aug 21, 2015, and Oct 10, 2017, with recruitment paused for 11 months by the funder, we recruited 1034 patients, of whom 750 were eligible and randomly assigned to the Portico valve group (n=381) or commercially available valve group (n=369). Mean age was 83 years (SD 7) and 395 (52·7%) patients were female. For the primary safety endpoint at 30 days, the event rate was higher in the Portico valve group than in the commercial valve group (52 [13·8%] vs 35 [9·6%]; absolute difference 4·2, 95% CI -0·4 to 8·8 [upper confidence bound {UCB} 8·1%]; pnon-inferiority=0·034, psuperiority=0·071). At 1 year, the rates of the primary efficacy endpoint were similar between the groups (55 [14·8%] in the Portico group vs 48 [13·4%] in the commercial valve group; difference 1·5%, 95% CI -3·6 to 6·5 [UCB 5·7%]; pnon-inferiority=0·0058, psuperiority=0·50). At 2 years, rates of death (80 [22·3%] vs 70 [20·2%]; p=0·40) or disabling stroke (10 [3·1%] vs 16 [5·0%]; p=0·23) were similar between groups. INTERPRETATION The Portico valve was associated with similar rates of death or disabling stroke at 2 years compared with commercial valves, but was associated with higher rates of the primary composite safety endpoint including death at 30 days. The first-generation Portico valve and delivery system did not offer advantages over other commercially available valves. FUNDING Abbott.
Collapse
Affiliation(s)
- Raj R Makkar
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
| | - Wen Cheng
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Ron Waksman
- Washington Hospital Center, Washington, DC, USA
| | | | - Tarun Chakravarty
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Mark Groh
- Mission Health and Hospitals, Asheville, NC, USA
| | | | - Mark J Russo
- Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, USA; Newark Beth Israel Medical Center, Newark, NY, USA
| | | | | | - Stephen Worthley
- Royal Adelaide Hospital, Adelaide, SA, Australia; Genesis Care, Sydney, NSW, Australia
| | - Bassem Chehab
- Cardiovascular Research Institute of Kansas, Ascension Via Christi Hospital, Wichita, KS, USA
| | | | - Ray Matthews
- University of Southern California, Los Angeles, CA, USA
| | - Ravi K Ramana
- Advocate Christ Medical Center, Oak Lawn, IL, USA; Heart Care Centers of Illinois, Palos Park, IL, USA
| | - Gerald Yong
- Fiona Stanley Hospital, Murdoch, WA, Australia
| | - Carlos E Ruiz
- Hackensack University Medical Center, Hackensack, NJ, USA
| | | | | | - Mamoo Nakamura
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | | | - Rahul Sharma
- Stanford University Medical Center, Stanford, CA, USA
| | - Sung-Han Yoon
- Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | | | | | | | - Deepak L Bhatt
- Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Gregory P Fontana
- Cardiovascular Institute, Los Robles Regional Medical Center, Thousand Oaks, CA, USA
| |
Collapse
|
32
|
Kassis N, Saad AM, Hariri E, Gad MM, Abdelfattah OM, Yun JJ, Reed GW, Puri R, Krishnaswamy A, Kapadia SR. Impact of Hospital Procedural Volume on Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve. JACC Cardiovasc Interv 2020; 13:1841-1843. [PMID: 32418873 DOI: 10.1016/j.jcin.2020.04.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Accepted: 04/07/2020] [Indexed: 10/24/2022]
|
33
|
Adams H, Roberts-Thomson R, Patterson T, Prendergast B, Redwood S. The Low-Risk TAVI Trials for Severe Aortic Stenosis: Future Implications for Australian and New Zealand Heart Teams. Heart Lung Circ 2020; 29:657-661. [PMID: 32115372 DOI: 10.1016/j.hlc.2020.01.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Accepted: 01/16/2020] [Indexed: 12/21/2022]
Affiliation(s)
- Heath Adams
- Department of Cardiology, St Thomas' Hospital, London, UK; Department of Cardiology, Royal Hobart Hospital, Hobart, Tas, Australia; School of Medicine, University of Tasmania, Hobart, Tas, Australia.
| | - Ross Roberts-Thomson
- Department of Cardiology, St Thomas' Hospital, London, UK; Department of Cardiology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Tiffany Patterson
- Department of Cardiology, St Thomas' Hospital, London, UK; Cardiovascular Department, King's College London, London, UK
| | | | - Simon Redwood
- Department of Cardiology, St Thomas' Hospital, London, UK; Cardiovascular Department, King's College London, London, UK
| |
Collapse
|
34
|
Barbanti M, Webb JG, Dvir D, Prendergast BD. Residual challenges in TAVI: moving forward. EUROINTERVENTION 2019; 15:857-866. [DOI: 10.4244/eij-d-19-00788] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
35
|
Mentias A, Saad M, Desai MY, Horwitz PA, Rossen JD, Panaich S, Elbadawi A, Qazi A, Sorajja P, Jneid H, Kapadia S, London B, Vaughan Sarrazin MS. Temporal Trends and Clinical Outcomes of Transcatheter Aortic Valve Replacement in Nonagenarians. J Am Heart Assoc 2019; 8:e013685. [PMID: 31668118 PMCID: PMC6898796 DOI: 10.1161/jaha.119.013685] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Background Contemporary outcomes of transcatheter aortic valve replacement (TAVR) in nonagenarians are unknown. Methods and Results We identified 13 544 nonagenarians (aged 90–100 years) who underwent TAVR between 2012 and 2016 using Medicare claims. Generalized estimating equations were used to study the change in short‐term outcomes among nonagenarians over time. We compared outcomes between nonagenarians and non‐nonagenarians undergoing TAVR in 2016. A mixed‐effect multivariable logistic regression was performed to determine predictors of 30‐day mortality in nonagenarians in 2016. A center was defined as a high‐volume center if it performed ≥100 TAVR procedures per year. After adjusting for changes in patients’ characteristics, risk‐adjusted 30‐day mortality declined in nonagenarians from 9.8% in 2012 to 4.4% in 2016 (P<0.001), whereas mortality for patients <90 years decreased from 6.4% to 3.5%. In 2016, 35 712 TAVR procedures were performed, of which 12.7% were in nonagenarians. Overall, in‐hospital mortality in 2016 was higher in nonagenarians compared with younger patients (2.4% versus 1.7%, P<0.05) but did not differ in analysis limited to high‐volume centers (2.2% versus 1.7%; odds ratio: 1.33; 95% CI, 0.97–1.81; P=0.07). Important predictors of 30‐day mortality in nonagenarians included in‐hospital stroke (adjusted odds ratio [aOR]: 8.67; 95% CI, 5.03–15.00), acute kidney injury (aOR: 4.11; 95% CI, 2.90–5.83), blood transfusion (aOR: 2.66; 95% CI, 1.81–3.90), respiratory complications (aOR: 2.96; 95% CI, 1.52–5.76), heart failure (aOR: 1.86; 95% CI, 1.04–3.34), coagulopathy (aOR: 1.59; 95% CI, 1.12–2.26; P<0.05 for all). Conclusions Short‐term outcomes after TAVR have improved in nonagenarians. Several procedural complications were associated with increased 30‐day mortality among nonagenarians.
Collapse
Affiliation(s)
- Amgad Mentias
- Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City IA
| | - Marwan Saad
- Cardiovascular Institute The Warren Alpert School of Medicine at Brown University Providence RI
| | - Milind Y Desai
- Heart and Vascular Institute Cleveland Clinic Foundation Cleveland OH
| | - Phillip A Horwitz
- Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City IA
| | - James D Rossen
- Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City IA
| | - Sidakpal Panaich
- Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City IA
| | - Ayman Elbadawi
- Division of Cardiovascular Medicine University of Texas Medical Branch Galveston TX
| | - Abdul Qazi
- Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City IA
| | - Paul Sorajja
- Minneapolis Heart Institute Foundation Abbott Northwestern Hospital Minneapolis MN
| | - Hani Jneid
- Division of Cardiology Baylor College of Medicine Houston TX
| | - Samir Kapadia
- Heart and Vascular Institute Cleveland Clinic Foundation Cleveland OH
| | - Barry London
- Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City IA
| | - Mary S Vaughan Sarrazin
- Department of Internal Medicine University of Iowa Carver College of Medicine Iowa City IA.,Comprehensive Access and Delivery Research and Evaluation Center (CADRE) Iowa City VA Medical Center Iowa City IA
| |
Collapse
|
36
|
Vemulapalli S, Carroll JD, Mack MJ. Volume and Outcomes for Transcatheter Aortic-Valve Replacement. Reply. N Engl J Med 2019; 381:1394-1395. [PMID: 31577892 DOI: 10.1056/nejmc1910012] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
37
|
Modeling the Volume-Outcome Relationship for TAVR. J Am Coll Cardiol 2019; 74:2115-2116. [DOI: 10.1016/j.jacc.2019.08.999] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/29/2019] [Revised: 07/10/2019] [Accepted: 08/04/2019] [Indexed: 11/24/2022]
|
38
|
Naidu SS, Daniels MJ, Elmariah S, Garcia S, Klein AJ, Feldman DN, Ing FF, Kavinsky CJ, Devireddy C, Mahmud E, Grines CL, Henry TD, Duffy PL, Amin ZC, Aronow HD, Banerjee S, Brilakis ES, Herrmann HC, Hijazi ZM, Jaffer FA, Latif F, Messenger JC, Parikh SA, Poulin M, Reilly JP, Rosenfield K, Szerlip M, Vincent RN, Cox DA, Baker D, Bhalla N, Bowen R, Camp C, Govender D, Haggstrom K, Hargus N, Hite D, Meikle J, Mylor B, Pierce V, Prince B, Roach J, Rudy J, Schludi B, Struck J, Tochterman A, Tolve M, William DM, Yowe S. Hot topics in interventional cardiology: Proceedings from the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Think Tank. Catheter Cardiovasc Interv 2019; 94:598-606. [DOI: 10.1002/ccd.28449] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Accepted: 08/01/2019] [Indexed: 11/07/2022]
Affiliation(s)
- Srihari S. Naidu
- Westchester Medical Center and New York Medical College Valhalla New York
| | | | | | - Santiago Garcia
- Minneapolis Heart Institute at Abbott Northwestern Hospital Minneapolis Minnesota
| | | | | | | | | | | | - Ehtisham Mahmud
- University of California, San Diego Sulpizio Cardiovascular Center San Diego California
| | | | | | - Peter L. Duffy
- FirstHealth Cardiology‐Pinehurst Pinehurst North Carolina
| | | | - Herbert D. Aronow
- Cardiovascular Institute/Brown Medical School Providence Rhode Island
| | | | | | | | | | | | - Faisal Latif
- University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
| | | | | | - Marie‐France Poulin
- Beth Israel Deaconess Medical Center/Harvard Medical School Boston Massachusetts
| | - John P. Reilly
- SUNY Stony Brook University Hospital Southampton New York
| | | | | | | | | | | | | | | | | | | | - Kurt Haggstrom
- Cordis, A Cardinal Health Company Santa Clara California
| | - Nick Hargus
- Cardiovascular Systems, Inc. Saint Paul Minnesota
| | - Denise Hite
- Cordis, A Cardinal Health Company Santa Clara California
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS, Kumbhani DJ, Ruiz CE, Thourani VH, Hanzel G, Gleason TG, Herrmann HC, Brindis RG, Bavaria JE. Procedural Volume and Outcomes for Transcatheter Aortic-Valve Replacement. N Engl J Med 2019; 380:2541-2550. [PMID: 30946551 DOI: 10.1056/nejmsa1901109] [Citation(s) in RCA: 249] [Impact Index Per Article: 49.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND During the introduction of transcatheter aortic-valve replacement (TAVR) in the United States, requirements regarding procedural volume were mandated by the Centers for Medicare and Medicaid Services as a condition of reimbursement. A better understanding of the relationship between hospital volume of TAVR procedures and patient outcomes could inform policy decisions. METHODS We analyzed data from the Transcatheter Valve Therapy Registry regarding procedural volumes and outcomes from 2015 through 2017. The primary analyses examined the association between hospital procedural volume as a continuous variable and risk-adjusted mortality at 30 days after transfemoral TAVR. Secondary analysis included risk-adjusted mortality according to quartile of hospital procedural volume. A sensitivity analysis was performed after exclusion of the first 12 months of transfemoral TAVR procedures at each hospital. RESULTS Of 113,662 TAVR procedures performed at 555 hospitals by 2960 operators, 96,256 (84.7%) involved a transfemoral approach. There was a significant inverse association between annualized volume of transfemoral TAVR procedures and mortality. Adjusted 30-day mortality was higher and more variable at hospitals in the lowest-volume quartile (3.19%; 95% confidence interval [CI], 2.78 to 3.67) than at hospitals in the highest-volume quartile (2.66%; 95% CI, 2.48 to 2.85) (odds ratio, 1.21; P = 0.02). The difference in adjusted mortality between a mean annualized volume of 27 procedures in the lowest-volume quartile and 143 procedures in the highest-volume quartile was a relative reduction of 19.45% (95% CI, 8.63 to 30.26). After the exclusion of the first 12 months of TAVR procedures at each hospital, 30-day mortality remained higher in the lowest-volume quartile than in the highest-volume quartile (3.10% vs. 2.61%; odds ratio, 1.19; 95% CI, 1.01 to 1.40). CONCLUSIONS An inverse volume-mortality association was observed for transfemoral TAVR procedures from 2015 through 2017. Mortality at 30 days was higher and more variable at hospitals with a low procedural volume than at hospitals with a high procedural volume. (Funded by the American College of Cardiology Foundation National Cardiovascular Data Registry and the Society of Thoracic Surgeons.).
Collapse
Affiliation(s)
- Sreekanth Vemulapalli
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - John D Carroll
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Michael J Mack
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Zhuokai Li
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - David Dai
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Andrzej S Kosinski
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Dharam J Kumbhani
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Carlos E Ruiz
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Vinod H Thourani
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - George Hanzel
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Thomas G Gleason
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Howard C Herrmann
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Ralph G Brindis
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| | - Joseph E Bavaria
- From the Division of Cardiology, Duke University Medical Center (S.V.), the Duke Clinical Research Institute (S.V., Z.L., D.D., A.S.K.), and the Department of Biostatistics and Bioinformatics, Duke University (A.S.K.) - all in Durham, NC; the Division of Cardiology, Department of Medicine, University of Colorado, Aurora (J.D.C.); Baylor Scott and White Heart Hospital, Plano (M.J.M.), and the Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas (D.J.K.) - both in Texas; the Division of Cardiology, Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ (C.E.R.); the Division of Cardiothoracic Surgery, Medstar Heart and Vascular Institute and Georgetown University, Washington, DC (V.H.T.); the Division of Cardiology, William Beaumont Hospital, Royal Oak, MI (G.H.); the University of Pittsburgh School of Medicine, Pittsburgh (T.G.G.); the Divisions of Cardiology (H.C.H.) and Cardiothoracic Surgery (J.E.B.), University of Pennsylvania, Philadelphia; and the Philip R. Lee Institute of Health Policy Studies, University of California, San Francisco, San Francisco (R.G.B.)
| |
Collapse
|
40
|
Ahmad M, Patel JN, Vipparthy SC, Divecha C, Barzallo PX, Kim M, Schrader SC, Barzallo M, Mungee S. Conscious Sedation Versus General Anesthesia in Transcatheter Aortic Valve Replacement: A Cost and Outcome Analysis. Cureus 2019; 11:e4812. [PMID: 31281765 PMCID: PMC6599466 DOI: 10.7759/cureus.4812] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Background Transcatheter aortic valve replacement (TAVR) has emerged as an alternative treatment for aortic stenosis in patients who are at moderate to high risk for surgical aortic valve replacement. The use of conscious sedation (CS) as compared with general anesthesia (GA) has shown better clinical outcomes for TAVR patients. Whether CS has any cost-benefit is still unknown. We analyze our local TAVR registry with a focus on the cost comparison between CS and GA for the TAVR population. Methods It is a retrospective chart review of 434 patients who received TAVR at our local center from December 2012 to April 2018. Patients who had their procedure aborted and those requiring a cardiopulmonary bypass or surgical conversion (16 patients) were excluded. The final sample size was 418. Patients were divided into two groups based on whether they received CS or GA. Primary outcomes were intensive care unit (ICU) hours, length of stay in hospital, readmission, or death at 30 days. The secondary outcome was the cost of TAVR admission. The cost was divided into direct and indirect costs. The student's T-test and chi-square tests were used for continuous and categorical variables, respectively. Adjusted logistic regression and multivariate analyses were run for primary and secondary outcomes. Results Of the 418 patients (age: 80.9±8.5, male: 52%) CS was given to 194 patients (46.4%) while GA was given in 224 patients(53.6%). The GA group had comparatively older age (81.8 vs. 80.0; p=0.03) and a higher average Society of Thoracic Surgery (STS) score (8.4 vs 5.7; p<0.001). Patients who received CS had a significantly shorter ICU stay (31.5 vs. 41.6 hours, p<0.001) and total days in the hospital (2.9 vs. 3.8 days, p=0.01). Readmission and mortality at 30 days were not different between the groups. There was no statistical difference in cost between the two groups ($72,809 vs. $71,497: p=0.656). Conclusion Using CS compared with GA improves morbidity for TAVR patients, in the form of ICU stay and the total length of stay in hospital. We did not find a significant difference in the cost of TAVR admission between CS and GA.
Collapse
Affiliation(s)
- Mansoor Ahmad
- Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, USA
| | - Jay N Patel
- Cardiology, University of Illinois College of Medicine at Peoria, Peoria, USA
| | - Sharath C Vipparthy
- Cardiology, University of Illinois College of Medicine at Peoria, Peoria, USA
| | - Chirag Divecha
- Cardiology, University of Illinois College of Medicine at Peoria, Peoria, USA
| | - Pablo X Barzallo
- Cardiology, University of Illinois College of Medicine at Peoria, Peoria, USA
| | - Minchul Kim
- Internal Medicine, University of Illinois College of Medicine at Peoria, Peoria, USA
| | - Steven C Schrader
- Anesthesiology, University of Illinois College of Medicine at Peoria, Peoria, USA
| | - Marco Barzallo
- Cardiology, University of Illinois College of Medicine at Peoria, Peoria, USA
| | - Sudhir Mungee
- Cardiology, University of Illinois College of Medicine at Peoria, Peoria, USA
| |
Collapse
|
41
|
George I, Kodali SK, Leon MB. Changing the Conversation to TAVR First! JACC Cardiovasc Interv 2019; 12:908-910. [DOI: 10.1016/j.jcin.2019.04.030] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Accepted: 04/19/2019] [Indexed: 10/26/2022]
|
42
|
Cormican D, Jayaraman A, Villablanca P, Ramakrishna H. TAVR Procedural Volumes and Patient Outcomes: Analysis of Recent Data. J Cardiothorac Vasc Anesth 2019; 34:545-550. [PMID: 31103384 DOI: 10.1053/j.jvca.2019.04.016] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Accepted: 04/18/2019] [Indexed: 01/31/2023]
Abstract
In less than 15 years, transcatheter aortic valve replacement (TAVR) has progressed from a procedure of last resort in patients at prohibitively high perioperative risk for major morbidity and mortality from surgical valve replacement to a viable alternative option to surgery in most patients with native (non-bicuspid) aortic valve stenosis. The number of medical centers offering TAVR has rapidly proliferated. There is mounting evidence that there are variations in patient outcomes associated with the yearly number of TAVR cases performed at each respective center. This review outlines the evolution of TAVR indications, common complications, the current literature addressing the association between procedural volumes and patient outcomes in TAVR, and offers a synopsis of risk factor assessment for patients considered for TAVR.
Collapse
Affiliation(s)
- Daniel Cormican
- Department of Anesthesiology, Allegheny General Hospital, Pittsburgh, PA
| | - Arun Jayaraman
- Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, AZ
| | | | - Harish Ramakrishna
- Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Phoenix, AZ.
| |
Collapse
|
43
|
Szydlowski G, Marelli D. TAVR 2.0: Professional Societies Collaborating to Measure, Assure, and Improve Quality. Ann Thorac Surg 2019; 108:1927-1928. [PMID: 30980820 DOI: 10.1016/j.athoracsur.2019.03.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2019] [Accepted: 03/05/2019] [Indexed: 10/27/2022]
Affiliation(s)
- Gary Szydlowski
- Division of Cardiovascular and Thoracic Surgery, Bayhealth Medical Center, 540 S Governors Ave, Dover, DE 19901.
| | - Daniel Marelli
- Division of Cardiovascular and Thoracic Surgery, Bayhealth Medical Center, 540 S Governors Ave, Dover, DE 19901
| |
Collapse
|
44
|
Improving Quality and Outcomes in TAVR: Turning Up the Volume? J Am Coll Cardiol 2019; 73:441-443. [PMID: 30704576 DOI: 10.1016/j.jacc.2018.09.093] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Accepted: 09/11/2018] [Indexed: 11/21/2022]
|